All PlansAdministrativeHigh impact
Voluntary nationwide recall: Sodium Chloride (Baxter – August 2026)
UPMC Health Plan·Pharmacy, Nephrology, Critical Care·Pharmacy
We identified it
Sep 12, 2026
Summary
Baxter International is recalling two lots (Y495523 and Y495523A) of 0.9% Sodium Chloride Injection due to fiberglass particle contamination that poses risk of local irritation, swelling, and life-threatening blood clots. Billing teams must identify affected patients, coordinate with providers and pharmacies to halt use, and document any related claims or adverse events for potential adjustments.
Action Required
Immediately: (1) Billing team must cross-reference patient records and claims for Sodium Chloride Injection (HCPCS J7131 or similar saline injection codes) administered from recalled lots Y495523 or Y495523A. (2) Flag affected claims in billing system and notify providers and patients to stop use. (3) Coordinate with pharmacy and providers to obtain recall status verification. (4) Document all affected claims and hold for potential reversal pending medical outcome review. (5) Monitor for any subsequent claims related to complications (blood clots, vessel blockage, local reactions) that may stem from recalled product use—these may require separate documentation or adjustment. (6) Maintain audit trail of all recalled product claims for compliance reporting to Baxter (888-229-0001) and FDA if requested. Contact Baxter Healthcare Center Monday-Friday, 7 a.m.–6 p.m. CST for lot verification assistance.